Skip to content
OpenCapital
Get started

abrdn Income Credit Strategies ACP Pharma — Goodwill

Other financials

Income statement

See full
Revenue$2.2B+18.2%
Net income-$459.0M-8.8%
EPS (diluted)-$0.71+10.1%

Balance sheet

See full
Cash & equivalents$1.3B-40.5%
Total debt$6.9B-5.9%
Total assets$12.9B-16.5%

Cash flow

See full
Operating cash flow$397.0M+318%
CapEx$114.0M+29.5%
Free cash flow$283.0M+205%

Valuation

See full
Market cap$0+1.6%

Profitability

See full
Gross margin-56.5%—
Net margin-3.4%-1.3pp
FCF margin20%—

Returns & leverage

See full
Return on equity-0.1%—
Debt / equity0.7×—

Where this comes from

Reported directly by abrdn Income Credit Strategies in its filing.

Tagged under the XBRL concept us-gaap:Goodwill.

The official record: abrdn Income Credit Strategies’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about abrdn Income Credit Strategies's pharma — goodwill.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is abrdn Income Credit Strategies's pharma — goodwill?
abrdn Income Credit Strategies (ACP) reported pharma — goodwill of $13M in Q1 2026.
How has abrdn Income Credit Strategies's pharma — goodwill changed year-over-year?
abrdn Income Credit Strategies's pharma — goodwill decreased by 0.0% year-over-year, from $13M to $13M.
What is the long-term trend for abrdn Income Credit Strategies's pharma — goodwill?
Over 4 years (2021 to 2025), abrdn Income Credit Strategies's pharma — goodwill has grown at a 0.0% compound annual growth rate (CAGR), from $52M to $52M.
What does pharma — goodwill mean?
The carrying value of goodwill associated with the pharmaceutical segment after accounting for any impairment charges. This reflects the current valuation of intangible synergies and market advantages acquired through past business combinations.